Genetic patent on cancer mouse faces opposition
The coalition of 25 animal welfare groups from 12 European countries yesterday launched a campaign to oppose the first European patent on a living animal. Harvard University was granted a provisional patent by the European Patent Office (EPO) in May last year for its 'Oncomouse' - a creature genetically engineered to contract cancer.
Yesterday, one month before the deadline for opposing the decision, the animal welfare groups submitted detailed legal arguments to the EPO that, because the European Patent Convention expressly prohibits any action that would be 'contrary to morality', the mouse could not be patented.
The patent is sweeping and would apply to dogs, rabbits or chimpanzees whose genes had similarly been manipulated. The coalition argues that 'the public would not readily accept the morality of genetically engineering a primate or a dog so that it should develop cancer'.
Joyce D'Silva, director of Compassion in World Farming, one of the British groups leading the campaign, warned that patent applications are pending for farm animals, including a transgenic chicken given the gene which produces growth hormone in cattle. Such chickens would grow faster and produce leaner meat.
Ms D'Silva said that legislation had created a 'duty of care' for all animal owners - no one legally can be deliberately cruel to an animal. However, the EPO's decision 'has enshrined a new form of animal ownership which carries no duty of care', she said. Instead, the Oncomouse was created in order to suffer.
The opposition groups also question just how well the EPO has assessed the usefulness of the patent. They argue that, increasingly, scientists are conducting cancer research using cells cultured in the laboratory and that to promote animal research would be a retrograde step.
In addition they say the patent is irreligious: humanity cannot claim to have 'invented' an animal; it is God who creates life.
Professor Sir David Weatherall, professor of clinical medicine at Oxford University, has already criticised the Oncomouse patent. In the textbook The New Genetics and Clinical Practice he warns that the public may reject the benefits of the new techniques.
- 1 Malaysian cyclist could face disciplinary action after 'Save Gaza' gloves protest
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
- 4 Students offered grants if they tweet pro-Israeli propaganda
- 5 Satellite full of sexually experimental geckos adrift in space, Russia loses control of mission
Israel-Gaza conflict: Israeli targeting policy under scrutiny after shellfire hits a mother and child, a school full of refugees and a doctor’s home
Iraq crisis: Isis orders Mosul shop keepers to cover mannequins
Comic Con 2014 attendees
Students offered grants if they tweet pro-Israeli propaganda
McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
Malaysia Airlines MH17 crash: Vladimir Putin is given 'one last chance' to end hostilities in Ukraine
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
The truth about conspiracy theories is that some require considering
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
Highly Attractive Package: Austen Lloyd: CITY - COMMERCIAL LITIGATION - GLOBAL...
£65000 - £75000 per annum + Benefits: Progressive Recruitment: The client is a...
£40000 - £45000 per annum: Ashdown Group: A well-established software house ba...